Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
11 04 2023
11 04 2023
Historique:
accepted:
21
07
2022
received:
07
03
2022
medline:
4
4
2023
pubmed:
12
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
Inadequate mobilization of peripheral blood progenitor cells (PBPCs) is a limiting factor to proceeding with autologous hematopoietic cell transplantation (auto-HCT). To assess the impact of clonal hematopoiesis (CH) on mobilization failure of PBPC for auto-HCT, we investigated the characteristics of poor mobilizers (with a total PBPC collection <2 × 106 CD34+ cells per kg) in a consecutive single-center cohort of 776 patients. Targeted error-corrected next-generation sequencing of 28 genes was performed in a nested case-control cohort of 90 poor mobilizers and 89 matched controls. CH was detected in 48 out of 179 patients (27%), with most patients carrying a single mutation. The presence of CH (detected at variant allele frequency [VAF] ≥ 1%) did not associate with poor mobilization potential (31% vs 22% in controls, odds ratio, 1.55; 95% confidence interval, 0.76-3.23; P = .238). PPM1D mutations were detected more often in poor mobilizers (P = .005). In addition, TP53 mutations in this cohort were detected exclusively in patients with poor mobilization potential (P = .06). The incidence of therapy-related myeloid neoplasms (t-MN) was higher among patients with mobilization failure (P = .014). Although poor mobilizers experienced worse overall survival (P = .019), this was not affected by the presence of CH. We conclude that CH at low VAF (1%-10%) is common at the time of stem cell mobilization. TP53 mutations and PPM1D mutations are associated with poor mobilization potential and their role in subsequent development of t-MN in these individuals should be established.
Identifiants
pubmed: 36219593
pii: 486755
doi: 10.1182/bloodadvances.2022007497
pmc: PMC10119633
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1269-1278Informations de copyright
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Leukemia. 2021 Jul;35(7):2125-2129
pubmed: 33184493
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
J Clin Oncol. 2019 Feb 10;37(5):375-385
pubmed: 30403573
Bone Marrow Transplant. 2012 Mar;47(3):342-51
pubmed: 21625224
EMBO J. 2000 Dec 1;19(23):6517-26
pubmed: 11101524
Blood. 2018 Apr 19;131(16):1846-1857
pubmed: 29311096
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
Blood. 2022 Oct 20;140(16):1753-1763
pubmed: 35512188
Blood. 2021 Nov 25;138(21):2093-2105
pubmed: 34125889
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
J Clin Oncol. 1995 Oct;13(10):2547-55
pubmed: 7595706
Blood. 2008 Jan 1;111(1):94-100
pubmed: 17895401
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Cancer. 2020 Feb 15;126(4):765-774
pubmed: 31742675
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
Blood. 2017 Aug 10;130(6):742-752
pubmed: 28483762
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Br J Haematol. 2021 May;193(4):841-844
pubmed: 33481245
Nat Commun. 2018 Jan 31;9(1):455
pubmed: 29386642
Am J Hematol. 2009 Jun;84(6):335-7
pubmed: 19384931
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6048-53
pubmed: 9177166
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Haematologica. 2020 Jul;105(7):e337-e339
pubmed: 31699793
Blood Adv. 2020 Mar 10;4(5):885-892
pubmed: 32150606
Blood. 2020 Apr 2;135(14):1161-1170
pubmed: 32243522
Blood Adv. 2020 Nov 24;4(22):5681-5689
pubmed: 33211826
Blood. 2018 Sep 13;132(11):1095-1105
pubmed: 29954749
Transfus Apher Sci. 2009 Aug;41(1):33-7
pubmed: 19540167
Nat Commun. 2020 Jun 12;11(1):2996
pubmed: 32533060
Leukemia. 2020 Dec;34(12):3256-3268
pubmed: 32203146
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
Br J Haematol. 2003 Feb;120(3):413-23
pubmed: 12580955
Br J Haematol. 2019 Aug;186(3):e31-e35
pubmed: 30859554
J Clin Oncol. 2017 May 10;35(14):1598-1605
pubmed: 28068180
Haematologica. 2013 Mar;98(3):364-70
pubmed: 23242601
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9
pubmed: 19925876
Lancet Oncol. 2017 Jan;18(1):112-121
pubmed: 27927582
Blood Adv. 2021 Apr 27;5(8):2115-2122
pubmed: 33877299